Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PREDICTion of Endocrine Resistance Using Molecular Imaging and Liquid Biopsy in Metastatic Breast Cancer (PREDICT-ER)

NCT07867925 is registered in ClinicalTrials.gov with Asan Medical Center as lead sponsor.

NCT NCT07867925
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07867925 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PREDICTion of Endocrine Resistance Using Molecular Imaging and Liquid Biopsy in Metastatic Breast Cancer (PREDICT-ER)
Lead sponsor
Asan Medical Center
Phase
Observational
Overall status
Not yet recruiting
Start date
October 13, 2026
Completion date
December 31, 2030
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer (hr+/ her2-)